Ruturaj Masvekar

548 total citations
18 papers, 353 citations indexed

About

Ruturaj Masvekar is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Virology. According to data from OpenAlex, Ruturaj Masvekar has authored 18 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Pathology and Forensic Medicine and 6 papers in Virology. Recurrent topics in Ruturaj Masvekar's work include HIV Research and Treatment (6 papers), Multiple Sclerosis Research Studies (6 papers) and Neuroinflammation and Neurodegeneration Mechanisms (6 papers). Ruturaj Masvekar is often cited by papers focused on HIV Research and Treatment (6 papers), Multiple Sclerosis Research Studies (6 papers) and Neuroinflammation and Neurodegeneration Mechanisms (6 papers). Ruturaj Masvekar collaborates with scholars based in United States, Poland and Puerto Rico. Ruturaj Masvekar's co-authors include Nazira El‐Hage, Bibiana Bielekova, Pamela E. Knapp, Kurt F. Hauser, Péter Kósa, Tianxia Wu, David A. Gewirtz, Myosotys Rodriguez, John J. Shacka and Seth M. Dever and has published in prestigious journals such as The Journal of Immunology, PLoS ONE and Annals of Neurology.

In The Last Decade

Ruturaj Masvekar

18 papers receiving 351 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruturaj Masvekar United States 13 119 83 81 80 54 18 353
Katy Emanuel United States 12 239 2.0× 79 1.0× 90 1.1× 46 0.6× 38 0.7× 26 441
Naomi Sibtain United Kingdom 9 112 0.9× 118 1.4× 107 1.3× 135 1.7× 35 0.6× 20 508
Alexander J. Gill United States 15 157 1.3× 180 2.2× 267 3.3× 43 0.5× 34 0.6× 20 569
Raha Dastgheyb United States 13 291 2.4× 107 1.3× 95 1.2× 17 0.2× 53 1.0× 48 565
Raisa Persidsky United States 9 152 1.3× 282 3.4× 171 2.1× 17 0.2× 95 1.8× 9 543
Crystal Bethel‐Brown United States 10 140 1.2× 147 1.8× 171 2.1× 10 0.1× 38 0.7× 15 425
Dominick L. Auci United States 13 76 0.6× 20 0.2× 20 0.2× 24 0.3× 59 1.1× 23 369
Jillian E. Wohler United States 12 72 0.6× 51 0.6× 9 0.1× 79 1.0× 20 0.4× 16 483
S Vlaho Germany 10 200 1.7× 33 0.4× 5 0.1× 69 0.9× 49 0.9× 24 513
Matthew J. Elrick United States 12 135 1.1× 38 0.5× 11 0.1× 32 0.4× 322 6.0× 16 575

Countries citing papers authored by Ruturaj Masvekar

Since Specialization
Citations

This map shows the geographic impact of Ruturaj Masvekar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruturaj Masvekar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruturaj Masvekar more than expected).

Fields of papers citing papers by Ruturaj Masvekar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruturaj Masvekar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruturaj Masvekar. The network helps show where Ruturaj Masvekar may publish in the future.

Co-authorship network of co-authors of Ruturaj Masvekar

This figure shows the co-authorship network connecting the top 25 collaborators of Ruturaj Masvekar. A scholar is included among the top collaborators of Ruturaj Masvekar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruturaj Masvekar. Ruturaj Masvekar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Kósa, Péter, et al.. (2022). Enhancing the clinical value of serum neurofilament light chain measurement. JCI Insight. 7(15). 9 indexed citations
2.
Agrawal, Neena, Nicole Y. Farhat, Ninet Sinaii, et al.. (2022). Neurofilament light chain in cerebrospinal fluid as a novel biomarker in evaluating both clinical severity and therapeutic response in Niemann-Pick disease type C1. Genetics in Medicine. 25(3). 100349–100349. 15 indexed citations
3.
Masvekar, Ruturaj, et al.. (2022). Drug library screen identifies inhibitors of toxic astrogliosis. Multiple Sclerosis and Related Disorders. 58. 103499–103499. 1 indexed citations
4.
Masvekar, Ruturaj, Péter Kósa, Kerry Dobbs, et al.. (2022). Prognostic value of serum/plasma neurofilament light chain for COVID ‐19‐associated mortality. Annals of Clinical and Translational Neurology. 9(5). 622–632. 19 indexed citations
5.
Masvekar, Ruturaj, Jonathan A. Phillips, Mika Komori, Tianxia Wu, & Bibiana Bielekova. (2021). Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity. Frontiers in Neuroscience. 15. 649876–649876. 14 indexed citations
6.
Inati, Sara K., Ariane Soldatos, Gina Norato, et al.. (2021). Seizure phenotype in CLN3 disease and its relation to other neurologic outcome measures. Journal of Inherited Metabolic Disease. 44(4). 1013–1020. 5 indexed citations
7.
Kósa, Péter, Tianxia Wu, Jonathan A. Phillips, et al.. (2020). Idebenone does not inhibit disability progression in primary progressive MS. Multiple Sclerosis and Related Disorders. 45. 102434–102434. 26 indexed citations
8.
Dang, An, Ninet Sinaii, Ruturaj Masvekar, et al.. (2020). Neurofilament light chain levels correlate with clinical measures in CLN3 disease. Genetics in Medicine. 23(4). 751–757. 14 indexed citations
9.
Masvekar, Ruturaj, et al.. (2019). Quantifications of CSF Apoptotic Bodies Do Not Provide Clinical Value in Multiple Sclerosis. Frontiers in Neurology. 10. 1241–1241. 10 indexed citations
10.
Masvekar, Ruturaj, et al.. (2018). Cerebrospinal fluid biomarkers link toxic astrogliosis and microglial activation to multiple sclerosis severity. Multiple Sclerosis and Related Disorders. 28. 34–43. 34 indexed citations
11.
Kósa, Péter, Mika Komori, Makoto Tanigawa, et al.. (2017). Molecular-based diagnosis of Multiple Sclerosis and its progressive stage. The Journal of Immunology. 198(Supplement_1). 55.23–55.23. 1 indexed citations
12.
Masvekar, Ruturaj, et al.. (2017). Productive infection of human neural progenitor cells by R5 tropic HIV-1. AIDS. 31(6). 753–764. 16 indexed citations
13.
Kósa, Péter, Mika Komori, Makoto Tanigawa, et al.. (2017). Molecular‐based diagnosis of multiple sclerosis and its progressive stage. Annals of Neurology. 82(5). 795–812. 42 indexed citations
14.
Arnatt, Christopher K., Yunyun Yuan, Ruturaj Masvekar, et al.. (2016). Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization. Bioorganic & Medicinal Chemistry. 24(22). 5969–5987. 28 indexed citations
15.
Masvekar, Ruturaj, Nazira El‐Hage, Kurt F. Hauser, & Pamela E. Knapp. (2015). GSK3β-activation is a point of convergence for HIV-1 and opiate-mediated interactive neurotoxicity. Molecular and Cellular Neuroscience. 65. 11–20. 19 indexed citations
16.
Hahn, Yun K., Ruturaj Masvekar, Ruqiang Xu, Kurt F. Hauser, & Pamela E. Knapp. (2015). Chronic HIV-1 Tat and HIV Reduce Rbfox3/NeuN: Evidence for Sex- Related Effects. Current HIV Research. 13(1). 10–20. 15 indexed citations
17.
Masvekar, Ruturaj, Nazira El‐Hage, Kurt F. Hauser, & Pamela E. Knapp. (2014). Morphine Enhances HIV-1SF162-Mediated Neuron Death and Delays Recovery of Injured Neurites. PLoS ONE. 9(6). e100196–e100196. 15 indexed citations
18.
El‐Hage, Nazira, Myosotys Rodriguez, Seth M. Dever, et al.. (2014). HIV-1 and Morphine Regulation of Autophagy in Microglia: Limited Interactions in the Context of HIV-1 Infection and Opioid Abuse. Journal of Virology. 89(2). 1024–1035. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katy Emanuel Breakdown of academic impact, for papers by Naomi Sibtain Breakdown of academic impact, for papers by Alexander J. Gill Breakdown of academic impact, for papers by Raha Dastgheyb Breakdown of academic impact, for papers by Raisa Persidsky Breakdown of academic impact, for papers by Crystal Bethel‐Brown Breakdown of academic impact, for papers by Dominick L. Auci Breakdown of academic impact, for papers by Jillian E. Wohler Breakdown of academic impact, for papers by S Vlaho Breakdown of academic impact, for papers by Matthew J. Elrick
Rankless by CCL
2026